Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and CAMBRIDGE, Mass., Dec. 18, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that Kate Haviland, Chief Executive Officer, will present a corporate overview and 2025 outlook at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 9:00 a.m. PT (12:00 p.m. ET).
马萨诸塞州剑桥，2024年12月18日 /PRNewswire/ -- Blueprint Medicines Corporation（纳斯达克：BPMC）今天宣布，首席执行官Kate Haviland将于2025年1月13日星期一上午9:00（东部时间中午12:00）在第43届J.P.摩根医疗健康大会上进行公司概述及2025展望的演讲。
A live webcast of the presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at . A replay of the webcast will be archived on Blueprint Medicines' website for 30 days following the presentation.
此次演讲的直播网络广播将可以通过访问Blueprint Medicines网站的投资者及媒体部分进行观看。在演讲后30天内，网络广播的重播将存档在Blueprint Medicines的网站上。
About Blueprint Medicines
关于Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
Blueprint Medicines是一家全球全方位集成的生物制药公司，致力于研发能够改变生命的药物。我们旨在通过解决两个核心关注领域的重要医疗问题来减轻人类痛苦：过敏/炎症和肿瘤学/血液学。我们的方法从针对疾病的根本原因开始，利用我们在核心关注领域的深厚科学知识和跨多种治疗手段的药物发现专业知识。我们在两种已获批准的药物方面拥有成功的记录，包括我们在美国和欧洲为系统性肥大细胞增多症(SM)患者带来的AYVAKIT/AYVAKYt（avapritinib）。凭借我们建立的研究、开发和商业能力及基础设施，我们现在的目标是通过推进一系列从早期科学到高级临床试验的项目，显著扩大我们的影响力，这些项目包括肥大细胞疾病（如SM和慢性荨麻疹）、乳腺癌和其他实体瘤。更多信息，请访问并在X（前Twitter；@BlueprintMeds）和LinkedIn上关注我们。
Trademarks
商标
Blueprint Medicines, AYVAKIT, AYVAKYT and associated logos are trademarks of Blueprint Medicines Corporation.
Blueprint Medicines、AYVAKIT、AYVAKYt及相关标志是Blueprint Medicines Corporation的商标。
SOURCE Blueprint Medicines Corporation
消息来源：Blueprint Medicines Corporation
